- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00331630
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Pilot Neoadjuvant Trial in Breast Cancer With Combination of ABI-007 (Abraxane) and GW572016 (Lapatinib)
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. Giving Abraxane together with lapatinib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving Abraxane together with lapatinib works in treating patients with stage I, stage II, or stage III breast cancer.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
OBJECTIVES:
Primary
- Determine the clinical response rate, as measured by clinical exam and imaging studies, in patients with stage I-III breast cancer treated with neoadjuvant Abraxane in combination with lapatinib.
Secondary
- Determine the pathologic complete response rate in patients treated with this regimen.
- Correlate proliferation (Ki67), apoptosis (cleaved caspase-3), and angiogenesis (vW, CD34) markers, measured before and after treatment, with tumor response in these patients.
- Conduct other correlative studies, including epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β), before and after treatment with this regimen to assess tumor response in these patients.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a pilot study. Patients are assigned to 1 of 2 treatment groups.
- Group 1: The first 10 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
- Group 2: The next 20 patients receive Abraxane and lapatinib (at a higher dose) as in group 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection and tumor biopsies periodically for correlative biomarker studies.
PROJECTED ACCRUAL: A total of 30 patients will be accrued to this study.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase temprana 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611-3013
- Northwestern University, Northwestern Medical Faculty Foundation
-
Chicago, Illinois, Estados Unidos, 60611
- Hematology-Oncology Associates of Illinois
-
Joliet, Illinois, Estados Unidos, 60432
- Midwest Center for Hematology/Oncology
-
Olympia Fields, Illinois, Estados Unidos, 60461
- Saint James Hospital and Health Centers Comprehensive Cancer Institute - Olympia Fields
-
-
Texas
-
Lubbock, Texas, Estados Unidos, 79410-1894
- Joe Arrington Cancer Research and Treatment Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
DISEASE CHARACTERISTICS:
Histologically confirmed breast cancer
- Clinical stage I-III disease
- Measurable disease defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm with spiral CT scan
- HER2/neu 3+ by immunohistochemistry or positive by fluorescent in situ hybridization
- No known brain metastases
- Hormone receptor status unspecified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Male or female
- Life expectancy > 12 weeks
- ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%
- WBC ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500 mm^3
- Platelet count ≥ 100,000/mm^3
- Total bilirubin normal
- AST and ALT ≤ 2.5 times upper limit of normal
- Creatinine normal OR creatinine clearance ≥ 60 mL/min
- LVEF ≥ 50% as measured by echocardiogram or MUGA scan
- No other malignancy within the past year
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to swallow and retain oral medication
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
- No ongoing or active infection
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled illness
- No gastrointestinal (GI) tract disease that would preclude ability to take oral medication
- No malabsorption syndrome
- No requirement for IV alimentation
- No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy, immunotherapy, radiotherapy, or hormonal therapy for breast cancer
- No prior treatment with epidermal growth factor receptor targeting therapies
- No prior surgical procedures affecting absorption
- No prior surgery for breast cancer
At least 14 days since prior and no concurrent CYP3A4 inducers, including any of the following:
Dexamethasone or dexamethasone equivalent dose ≥ 1.5 mg/day, including any of the following:
- Cortisone (≥ 50 mg/day)
- Hydrocortisone (≥ 40 mg/day)
- Prednisone (≥ 10 mg/day)
- Methylprednisolone (≥ 8 mg/day)
- Phenytoin
- Carbamazepine
- Phenobarbital
- Efavirenz
- Nevirapine
- Rifampin
- Rifabutin
- Rifapentine
- Hypericum perforatum (St. John's wort)
- Modafinil
At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:
- Clarithromycin
- Erythromycin
- Troleandomycin
- Delavirdine
- Ritonavir
- Indinavir
- Saquinavir
- Nelfinavir
- Amprenavir
- Lopinavir
- Itraconazole
- Ketoconazole
- Voriconazole
- Fluconazole (doses up to 150 mg/day are permitted)
- Nefazodone
- Fluvoxamine
- Verapamil
- Diltiazem
- Cimetidine
- Aprepitant
- Grapefruit or its juice
- At least 6 months since prior and no concurrent amiodarone
At least 2 days since prior and no concurrent gastric pH modifiers*, including any of the following:
- Cimetidine
- Ranitidine
- Nizatidine
- Famotidine
- Omeprazole
- Esomeprazole
- Rabeprazole
- Pantoprazole
- Lansoprazole
- NOTE: *Antacids are allowed within 1 hour before and after administration of study drug
- No other concurrent investigational agents
- No other concurrent anticancer therapy, including chemotherapy, radiotherapy, immunotherapy, or antitumor hormonal therapy
- No concurrent herbal (alternative) medicines
- No concurrent combination antiretroviral therapy for HIV-positive patients
- Concurrent bisphosphonates allowed
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Treatment arm
30 patients receive Abraxane IV over 30 minutes on day 1 and oral lapatinib once daily on days 1-21.
Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
|
Oral lapatinib is taken once daily on days 1-21 of each treatment cycle.
Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Otros nombres:
30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle.
Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Clinical Response Rate (cRR)
Periodo de tiempo: At Baseline, then before each treatment cycle begins and after 4 cycles of study treatment (1 cycle = 21 days)
|
cRR measured by RECIST for target lesions assessed by clinical exam+ mammogram+ ultrasound (US). cRR is defined as number of patients who's best response in any of the assessments (clinical exam/mammogram/US) is CR+PR. Response will be defined as one of the following in either clinical exam, mammogram or US: Complete Response (CR)-Disappearance of all target lesions. Partial Response (PR)>=30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum. Stable Disease-neither sufficient shrinkage to qualify for Partial disease nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum LD while on study. Progressive Disease <=20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
At Baseline, then before each treatment cycle begins and after 4 cycles of study treatment (1 cycle = 21 days)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Pathologic Complete Response (pCR)
Periodo de tiempo: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) and at surgery
|
Pathologic Complete Response (pCR) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days) and at surgery.
This will be defined as the number of patients that show a pCR after surgery.
pCR is defined as the absence of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes.
|
At baseline, then after 4 cycles of study treatment (1 cycle = 21 days ) and at surgery
|
Proliferation (Ki67) Measured at Baseline and After Completion of Study Treatment
Periodo de tiempo: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Correlation of proliferation (Ki67) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days).
Ki67 scoring was performed based on degree of staining (0= no staining, 1=weak nuclear staining, 2=moderate nuclear staining, 3=strong nuclear staining).
Ki67 scores were counted on a maximum of 10 randomly selected x40 high-power fields with an eyepiece grid of 10x10 squares containing representative sections of tumor and calculated as percentage of positively stained cells to total tumor cells (Percent Score method) Ki67 labeling Index (LI) as assessed by counting a maximum of 1,000 malignant cells at x400 magnification.
|
At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Apoptosis (Cleaved Caspase-3) Measured at Baseline and After Completion of Study Treatment
Periodo de tiempo: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Apoptosis/cleaved caspase-3 (CC3) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days).
Scoring was based on the degree of staining (0=more than 90% of tumor cells with no staining, 1= more than 90% of tumor cells have weak staining, 2= more than 90% of tumor cells have moderate staining, 3= more than 90% of tumor cells have strong staining).
CC3 scores were counted on a maximum of 10 randomly selected x40 high-power fields with an eyepiece grid of 10x10 squares containing representative sections of tumor and calculated as percentage of positively stained cells to total tumor cells (Percent Score method) CC3 labeling Index (LI) as assessed by counting a maximum of 1,000 malignant cells at x400 magnification.
|
At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Angiogenesis (vW, CD34) Markers as Measured at Baseline and After Completion of Study Treatment
Periodo de tiempo: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Angiogenesis (vW, CD34) markers will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days). Expressions were analyzed by light microscopy in invasive breast cancer regions. Tumor cells were assigned a score: 0 = no staining
|
At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Epidermal Growth Factor Receptor (EGFR), and Matrix Metalloproteinases (MMPs), Measured at Baseline and After Completion of Study Treatment
Periodo de tiempo: At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Epidermal growth factor receptor (EGFR), HER2/neu, matrix metalloproteinases (MMPs), and transforming growth factor (TGF-β) will be assessed by breast biopsy at baseline and after 4 cycles of study treatment (1 cycle = 21 days) with expressions analyzed by light microscopy in invasive breast cancer regions. MMP2 cytoplasmic staining intensity was assigned a score: 0=no reactivity,
Greater than or equal to 2+ score was considered positive for expression. EGFR membrane staining was assigned a score: 0 = no staining or faint staining in less than 10% of cells
|
At baseline, then after 4 cycles of study treatment (1 cycle = 21 days )
|
Side Effects From the Combination of Abraxane and Lapatinib
Periodo de tiempo: At baseline, then before the start of each study treatment cycle (1 cycle = 21 days) begins
|
Side effects from the combination of Abraxane and Lapatinib will be assessed using CTCAE 3.0. Side effects that were related to study treatment and grade 3 or higher were collected where: Grade 1= Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life-threatening Grade 5 = Death |
At baseline, then before the start of each study treatment cycle (1 cycle = 21 days) begins
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Circulating Tumor Cell Measurement
Periodo de tiempo: At baseline, then before each study treatment cycle begins (1 cycle = 21 days)
|
Circulating tumor cell measurement will be assessed by lab tests done at baseline, then before each study treatment cycle begins (1 cycle = 21 days)
|
At baseline, then before each study treatment cycle begins (1 cycle = 21 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Virginia G. Kaklamani, MD, Northwestern University
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades de la piel
- Neoplasias
- Neoplasias por sitio
- Enfermedades de los senos
- Neoplasias de mama
- Mecanismos moleculares de acción farmacológica
- Inhibidores de enzimas
- Agentes antineoplásicos
- Moduladores de tubulina
- Agentes antimitóticos
- Moduladores de mitosis
- Agentes antineoplásicos, fitogénicos
- Inhibidores de la proteína quinasa
- Paclitaxel
- Paclitaxel unido a albúmina
- Lapatinib
Otros números de identificación del estudio
- NU 05B2 (Otro identificador: Northwestern University)
- STU00007257 (Otro identificador: Northwestern University IRB)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer de mama
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated Hospital of Zhengzhou University y otros colaboradoresTerminadoLa guía de aplicación clínica de Conebeam Breast CTPorcelana
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
Ensayos clínicos sobre lapatinib ditosylate
-
Institut Paoli-CalmettesSuspendido
-
GlaxoSmithKlineTerminado
-
German Breast GroupTerminadoCáncer de mama metastásicoAlemania
-
R-PharmGlaxoSmithKlineTerminadoCáncer de mama localmente avanzado o metastásicoEstados Unidos, Italia, Australia
-
Tragara Pharmaceuticals, Inc.Terminado
-
GlaxoSmithKlineTerminadoNeoplasias De MamaReino Unido, Estados Unidos, Perú, Israel, Polonia, Federación Rusa, Corea, república de, Tailandia, Pakistán, Hungría, India, Canadá, Francia, México, Malasia, Singapur
-
University of Alabama at BirminghamGlaxoSmithKline; AbbVie; Breast Cancer Research Foundation of AlabamaActivo, no reclutandoCáncer de mama triple negativo metastásicoEstados Unidos
-
University of Alabama at BirminghamGlaxoSmithKlineTerminadoCáncer de ovariosEstados Unidos
-
GlaxoSmithKlineTerminadoCáncer colonrectalEstados Unidos, Canadá
-
GlaxoSmithKlineTerminado